SOLD OUT!

Earn Up to 2 Hours of CME!

Zoom Platform

Pre-Registration is required.

Registration Fee: $25.00

Program Description

This CME program is designed to provide healthcare professionals with an in-depth understanding of the evolving landscape of endocrine-resistant metastatic breast cancer (mBC), with a particular focus on ESR1 mutations and the role of oral selective estrogen receptor degraders (SERDs). Through a comprehensive review of current research, clinical trial data, and biomarker investigations, participants will gain practical insights into identifying patients most likely to benefit from novel therapies and integrating these agents into individualized treatment plans. The program emphasizes clinical application, adverse event management, and evidence-based decision-making to optimize outcomes for patients with ER-positive, HER2-negative mBC who are experiencing disease progression despite standard endocrine therapy and CDK4/6 inhibition.